Literature DB >> 28535112

Is HBV prophylaxis required during CLL treatment with ibrutinib?

Alessandra Tedeschi1, Anna Maria Frustaci1, Maddalena Mazzucchelli1, Roberto Cairoli1, Marco Montillo1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28535112     DOI： 10.1080/10428194.2017.1317094

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  1 in total

1.  Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study.

Authors:  Idanna Innocenti; Gianluigi Reda; Andrea Visentin; Marta Coscia; Marina Motta; Roberta Murru; Riccardo Moia; Massimo Gentile; Elsa Pennese; Francesca Maria Quaglia; Francesco Albano; Ramona Cassin; Marina Deodato; Claudia Ielo; Anna Maria Frustaci; Alfonso Piciocchi; Arianna Rughini; Valentina Arena; Daniela Di Sevo; Annamaria Tomasso; Francesco Autore; Giovanni Del Poeta; Lydia Scarfò; Francesca Romana Mauro; Alessandra Tedeschi; Livio Trentin; Maurizio Pompili; Robin Foà; Paolo Ghia; Antonio Cuneo; Luca Laurenti
Journal:  Haematologica       Date:  2022-06-01       Impact factor: 11.047
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.